Direct-to-consumer virtual operator Done has opened 30 physical clinic locations across the country.
Like Done’s virtual services, these new locations will be focused on providing ADHD care and medications to adults.
This move comes less than a year after the Drug Enforcement Administration (DEA) released a proposed rule that would essentially end the virtual telehealth flexibilities that had allowed companies like Done to prescribe controlled substances without an in-person visit.
After a wave of backlash on the proposal, the DEA announced it would extend virtual care allowances until December 2024. Still, some companies are looking to future-proof themselves if the DEA takes away these flexibilities.
Done is one of the companies pivoting from its virtual-only approach and moving to a hybrid model. The startup has opened locations in California, Texas, New York, Florida, Pennsylvania, Colorado and 25 other states. Patients can meet with a board-certified clinician face-to-face at these locations.
Done will continue to operate its virtual care platform and offer consultations with board-certified clinicians, diagnoses, support and medication delivery. Done’s patients can complete the ADHD self-assessment scale and are then evaluated by a psychiatrist or nurse practitioner. Once a patient is enrolled in the treatment, providers will create a personalized treatment plan for them.
The company notes that it uses multi-state Prescription Drug Monitoring Programs, monthly check-ins and biannual reviews to ensure that the medications prescribed are not being misused. It also developed a new digital tool called Future Health, which gives mental health clinicians “actionable, data-informed insights to refine speciality care for a variety of conditions.”
Founded in 2019, Done got its start as a virtual provider of ADHD medications. The startup was one of several companies that has come under public scrutiny for their prescribing practices of ADHD medications.
Last year the Wall Street Journal reported that the Drug Enforcement Administration was investigating Done but the company denied this assertion at the time of the report.
But Done was not the only company to face backlash for its prescribing practices. Digital health unicorn Cerebral was reportedly the subject of a Department of Justice (DOJ) investigation for a potential violation of the Controlled Substance Act. Cerebral has since decided to end its prescribing of controlled substances.
Companies featured in this article:
